Axsome Advances Sleep Disorder Pipeline as Sunosi Prescriptions Increase in Q3
Q3 results highlight increased Sunosi prescriptions and advancements in Axsome’s late-stage trials for narcolepsy and shift work disorder.
Tag: solriamfetol
All
Latest
All
Latest
Axsome Presents Positive Q1 Results, Advances in Sleep Medicine Pipeline
The company highlighted recently reported phase 3 results for AXS-12 in narcolepsy treatment, alongside revenue growth for Sunosi.
All
LatestSorry, No Posts Found
Study Compares Efficacy of Wakefulness-Promoting Agents in Sleep Apnea
In a study comparing the effectiveness of wakefulness-promoting agents, researchers pinpointed which drug is likely the most effective in treating excessive daytime sleepiness for people with sleep apnea.
Read More
Axsome’s Sunosi Sees Strong Growth in Prescription Numbers
Axsome Therapeutics reported first-quarter corporate updates, noting a growing patient base for Sunosi and progress for its narcolepsy drug candidate AXS-12.
Read More
OSA Patients May Discontinue Wakefulness Drugs Due to Side Effects
According to a review of 14 trials involving patients with OSA already on conventional therapy, adverse events associated with several wakefulness drugs increased the risk of discontinuation in several trials.
Read More
Axsome Presents Secondary Endpoints for Solriamfetol in SHARP Study
Solriamfetol is being trialed in 59 patients with excessive daytime sleepiness associated with obstructive sleep apnea and impaired cognitive function.
Read More
Axsome Licenses Pharmanovia to Commercialize Sunosi in Europe
The license agreement will expand the availability of Sunosi, a medicine used to reduce excessive daytime sleepiness in adults with narcolepsy or OSA, across Europe and MENA.
Read More
Could a History of Depression Change Outcomes for Sleep Apnea Patients Treated for EDS?
New research looked at whether a history of depression changed outcomes in patients with sleep apnea or narcolepsy who use solriamfetol to control excessive daytime sleepiness.
Read More